转移性肾细胞癌循环肿瘤细胞的纵向分子分析
研究纳入104例转移性肾细胞癌患者的457份纵向液体活检,采用循环肿瘤细胞捕获与自动显微平台分析循环肿瘤细胞计数及HLA I与PD-L1表达。影像学缓解者循环肿瘤细胞丰度持续较低;循环肿瘤细胞计数轨迹最高四分位者总生存较短;免疫治疗中HLA I与PD-L1比值下降而酪氨酸激酶抑制剂治疗中未下降。
要点
- 影像学缓解的转移性肾细胞癌患者治疗全程循环肿瘤细胞丰度显著较低。
- 循环肿瘤细胞计数年增长>0.12个/mL者总生存较短(中位17.0个月 vs 21.1个月,P<.001)。
- HLA I与PD-L1比值轨迹最高四分位(年≥0.0012)者总生存较短(中位18.4个月 vs 21.2个月,P=.003)。
核心结论
- 这是迄今首项转移性肾细胞癌大型纵向循环肿瘤细胞研究,发现循环肿瘤细胞计数及其随时间变化和HLA I与PD-L1比值变化具有预后意义。
- 这些关于肿瘤负荷及肿瘤细胞分子谱随不同治疗变化的发现,为预测和监测转移性肾细胞癌免疫治疗反应提供了潜在生物标志物。
研究设计与样本
- 研究纳入104例转移性肾细胞癌患者,来自前瞻性队列研究或II期多中心适应性免疫治疗试验两项研究之一。
- 共采集457份纵向液体活检,采用新型循环肿瘤细胞捕获与自动显微平台分析循环肿瘤细胞计数及HLA I和程序性死亡配体1(PD-L1)表达。
主要发现
- 影像学缓解的患者在整个治疗过程中循环肿瘤细胞丰度显著较低。
- 循环肿瘤细胞计数轨迹位于最高四分位(年>0.12个循环肿瘤细胞/mL)的患者总生存较短(中位17.0个月 vs 21.1个月,P<.001)。
- 接受免疫治疗的患者HLA I与PD-L1比值在整个治疗过程中下降,而接受酪氨酸激酶抑制剂的患者未下降。
- HLA I与PD-L1比值轨迹位于最高四分位(年≥0.0012)的患者总生存显著较短(中位18.4个月 vs 21.2个月,P=.003)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Liquid biopsies in metastatic renal cell carcinoma (mRCC) provide a unique approach to understand the molecular basis of treatment response and resistance. This is particularly important in the context of immunotherapies, which target key immune-tumor interactions. Unlike metastatic tissue biopsies, serial real-time profiling of mRCC is feasible with our noninvasive circulating tumor cell (CTC) approach. METHODS: We collected 457 longitudinal liquid biopsies from 104 patients with mRCC enrolled in one of two studies, either a prospective cohort or a phase II multicenter adaptive immunotherapy trial. Using a novel CTC capture and automated microscopy platform, we profiled CTC enumeration and expression of HLA I and programmed cell death-ligand 1 (PD-L1). Given their diametric immunological roles, we focused on the HLA I to PD-L1 ratio (HP ratio). RESULTS: Patients with radiographic responses showed significantly lower CTC abundances throughout treatment. Furthermore, patients whose CTC enumeration trajectory was in the highest quartile (> 0.12 CTCs/mL annually) had shorter overall survival (median 17.0 months v 21.1 months, P < .001). Throughout treatment, the HP ratio decreased in patients receiving immunotherapy but not in patients receiving tyrosine kinase inhibitors. Patients with an HP ratio trajectory in the highest quartile (≥ 0.0012 annually) displayed significantly shorter overall survival (median 18.4 months v 21.2 months, P = .003). CONCLUSION: In the first large longitudinal CTC study in mRCC to date to our knowledge, we identified the prognostic importance of CTC enumeration and the change over time of both CTC enumeration and the HP ratio. These insights into changes in both tumor burden and the molecular profile of tumor cells in response to different treatments provide potential biomarkers to predict and monitor response to immunotherapy in mRCC.
引用
- Bootsma M, McKay RR, Emamekhoo H, et al. Longitudinal Molecular Profiling of Circulating Tumor Cells in Metastatic Renal Cell Carcinoma. J Clin Oncol. 2022. PMID: 35617646. doi:10.1200/JCO.22.00219
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。